Medical Care
Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 562550
- Pages: 125
- Figures: 128
- Views: 8
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Radioisotopes for Nuclear Medicine Diagnosis and Treatment market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
NRG
NTP Radioisotopes
JSC Isotope
ANSTO
China National Nuclear Corporation (CNNC)
IRE ELIT
Nordion
Polatom
Segment by Type
Carbon-14
Technetium-99m
Iodine-131
Iodine-125
Others
Segment by Application
Nuclear Medicine Diagnosis
Nuclear Medicine Treatment
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Radioisotopes for Nuclear Medicine Diagnosis and Treatment study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Radioisotopes for Nuclear Medicine Diagnosis and Treatment market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
NRG
NTP Radioisotopes
JSC Isotope
ANSTO
China National Nuclear Corporation (CNNC)
IRE ELIT
Nordion
Polatom
Segment by Type
Carbon-14
Technetium-99m
Iodine-131
Iodine-125
Others
Segment by Application
Nuclear Medicine Diagnosis
Nuclear Medicine Treatment
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Radioisotopes for Nuclear Medicine Diagnosis and Treatment study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Radioisotopes for Nuclear Medicine Diagnosis and Treatment: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Carbon-14
1.2.3 Technetium-99m
1.2.4 Iodine-131
1.2.5 Iodine-125
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Nuclear Medicine Diagnosis
1.3.3 Nuclear Medicine Treatment
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Estimates and Forecasts 2020-2031
2.2 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Carbon-14 Market Size by Players
3.3.2 Technetium-99m Market Size by Players
3.3.3 Iodine-131 Market Size by Players
3.3.4 Iodine-125 Market Size by Players
3.3.5 Others Market Size by Players
3.4 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type (2020-2031)
6.4 North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type (2020-2031)
7.4 Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type (2020-2031)
8.4 Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type (2020-2031)
9.4 Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type (2020-2031)
10.4 Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 NRG
11.1.1 NRG Corporation Information
11.1.2 NRG Business Overview
11.1.3 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.1.4 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.1.5 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Product in 2024
11.1.6 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application in 2024
11.1.7 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Geographic Area in 2024
11.1.8 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
11.1.9 NRG Recent Developments
11.2 NTP Radioisotopes
11.2.1 NTP Radioisotopes Corporation Information
11.2.2 NTP Radioisotopes Business Overview
11.2.3 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.2.4 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.2.5 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Product in 2024
11.2.6 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application in 2024
11.2.7 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Geographic Area in 2024
11.2.8 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
11.2.9 NTP Radioisotopes Recent Developments
11.3 JSC Isotope
11.3.1 JSC Isotope Corporation Information
11.3.2 JSC Isotope Business Overview
11.3.3 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.3.4 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.3.5 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Product in 2024
11.3.6 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application in 2024
11.3.7 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Geographic Area in 2024
11.3.8 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
11.3.9 JSC Isotope Recent Developments
11.4 ANSTO
11.4.1 ANSTO Corporation Information
11.4.2 ANSTO Business Overview
11.4.3 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.4.4 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.4.5 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Product in 2024
11.4.6 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application in 2024
11.4.7 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Geographic Area in 2024
11.4.8 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
11.4.9 ANSTO Recent Developments
11.5 China National Nuclear Corporation (CNNC)
11.5.1 China National Nuclear Corporation (CNNC) Corporation Information
11.5.2 China National Nuclear Corporation (CNNC) Business Overview
11.5.3 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.5.4 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.5.5 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Product in 2024
11.5.6 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application in 2024
11.5.7 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Geographic Area in 2024
11.5.8 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
11.5.9 China National Nuclear Corporation (CNNC) Recent Developments
11.6 IRE ELIT
11.6.1 IRE ELIT Corporation Information
11.6.2 IRE ELIT Business Overview
11.6.3 IRE ELIT Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.6.4 IRE ELIT Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.6.5 IRE ELIT Recent Developments
11.7 Nordion
11.7.1 Nordion Corporation Information
11.7.2 Nordion Business Overview
11.7.3 Nordion Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.7.4 Nordion Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.7.5 Nordion Recent Developments
11.8 Polatom
11.8.1 Polatom Corporation Information
11.8.2 Polatom Business Overview
11.8.3 Polatom Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.8.4 Polatom Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.8.5 Polatom Recent Developments
12 Radioisotopes for Nuclear Medicine Diagnosis and TreatmentIndustry Chain Analysis
12.1 Radioisotopes for Nuclear Medicine Diagnosis and Treatment Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Radioisotopes for Nuclear Medicine Diagnosis and Treatment: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Carbon-14
1.2.3 Technetium-99m
1.2.4 Iodine-131
1.2.5 Iodine-125
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Nuclear Medicine Diagnosis
1.3.3 Nuclear Medicine Treatment
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Estimates and Forecasts 2020-2031
2.2 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Carbon-14 Market Size by Players
3.3.2 Technetium-99m Market Size by Players
3.3.3 Iodine-131 Market Size by Players
3.3.4 Iodine-125 Market Size by Players
3.3.5 Others Market Size by Players
3.4 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type (2020-2031)
6.4 North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type (2020-2031)
7.4 Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type (2020-2031)
8.4 Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type (2020-2031)
9.4 Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Type (2020-2031)
10.4 Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 NRG
11.1.1 NRG Corporation Information
11.1.2 NRG Business Overview
11.1.3 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.1.4 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.1.5 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Product in 2024
11.1.6 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application in 2024
11.1.7 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Geographic Area in 2024
11.1.8 NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
11.1.9 NRG Recent Developments
11.2 NTP Radioisotopes
11.2.1 NTP Radioisotopes Corporation Information
11.2.2 NTP Radioisotopes Business Overview
11.2.3 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.2.4 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.2.5 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Product in 2024
11.2.6 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application in 2024
11.2.7 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Geographic Area in 2024
11.2.8 NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
11.2.9 NTP Radioisotopes Recent Developments
11.3 JSC Isotope
11.3.1 JSC Isotope Corporation Information
11.3.2 JSC Isotope Business Overview
11.3.3 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.3.4 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.3.5 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Product in 2024
11.3.6 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application in 2024
11.3.7 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Geographic Area in 2024
11.3.8 JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
11.3.9 JSC Isotope Recent Developments
11.4 ANSTO
11.4.1 ANSTO Corporation Information
11.4.2 ANSTO Business Overview
11.4.3 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.4.4 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.4.5 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Product in 2024
11.4.6 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application in 2024
11.4.7 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Geographic Area in 2024
11.4.8 ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
11.4.9 ANSTO Recent Developments
11.5 China National Nuclear Corporation (CNNC)
11.5.1 China National Nuclear Corporation (CNNC) Corporation Information
11.5.2 China National Nuclear Corporation (CNNC) Business Overview
11.5.3 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.5.4 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.5.5 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Product in 2024
11.5.6 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application in 2024
11.5.7 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Geographic Area in 2024
11.5.8 China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
11.5.9 China National Nuclear Corporation (CNNC) Recent Developments
11.6 IRE ELIT
11.6.1 IRE ELIT Corporation Information
11.6.2 IRE ELIT Business Overview
11.6.3 IRE ELIT Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.6.4 IRE ELIT Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.6.5 IRE ELIT Recent Developments
11.7 Nordion
11.7.1 Nordion Corporation Information
11.7.2 Nordion Business Overview
11.7.3 Nordion Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.7.4 Nordion Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.7.5 Nordion Recent Developments
11.8 Polatom
11.8.1 Polatom Corporation Information
11.8.2 Polatom Business Overview
11.8.3 Polatom Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Features and Attributes
11.8.4 Polatom Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue and Gross Margin (2020-2025)
11.8.5 Polatom Recent Developments
12 Radioisotopes for Nuclear Medicine Diagnosis and TreatmentIndustry Chain Analysis
12.1 Radioisotopes for Nuclear Medicine Diagnosis and Treatment Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioisotopes for Nuclear Medicine Diagnosis and Treatment as of 2024)
Table 11. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Companies Headquarters
Table 13. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application (2026-2031) & (US$ Million)
Table 21. Radioisotopes for Nuclear Medicine Diagnosis and Treatment High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Growth Accelerators and Market Barriers
Table 25. North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Growth Accelerators and Market Barriers
Table 27. Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Investment Opportunities and Key Challenges
Table 31. Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. NRG Corporation Information
Table 35. NRG Description and Major Businesses
Table 36. NRG Product Features and Attributes
Table 37. NRG Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. NRG Revenue Proportion by Product in 2024
Table 39. NRG Revenue Proportion by Application in 2024
Table 40. NRG Revenue Proportion by Geographic Area in 2024
Table 41. NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
Table 42. NRG Recent Developments
Table 43. NTP Radioisotopes Corporation Information
Table 44. NTP Radioisotopes Description and Major Businesses
Table 45. NTP Radioisotopes Product Features and Attributes
Table 46. NTP Radioisotopes Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. NTP Radioisotopes Revenue Proportion by Product in 2024
Table 48. NTP Radioisotopes Revenue Proportion by Application in 2024
Table 49. NTP Radioisotopes Revenue Proportion by Geographic Area in 2024
Table 50. NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
Table 51. NTP Radioisotopes Recent Developments
Table 52. JSC Isotope Corporation Information
Table 53. JSC Isotope Description and Major Businesses
Table 54. JSC Isotope Product Features and Attributes
Table 55. JSC Isotope Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. JSC Isotope Revenue Proportion by Product in 2024
Table 57. JSC Isotope Revenue Proportion by Application in 2024
Table 58. JSC Isotope Revenue Proportion by Geographic Area in 2024
Table 59. JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
Table 60. JSC Isotope Recent Developments
Table 61. ANSTO Corporation Information
Table 62. ANSTO Description and Major Businesses
Table 63. ANSTO Product Features and Attributes
Table 64. ANSTO Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. ANSTO Revenue Proportion by Product in 2024
Table 66. ANSTO Revenue Proportion by Application in 2024
Table 67. ANSTO Revenue Proportion by Geographic Area in 2024
Table 68. ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
Table 69. ANSTO Recent Developments
Table 70. China National Nuclear Corporation (CNNC) Corporation Information
Table 71. China National Nuclear Corporation (CNNC) Description and Major Businesses
Table 72. China National Nuclear Corporation (CNNC) Product Features and Attributes
Table 73. China National Nuclear Corporation (CNNC) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. China National Nuclear Corporation (CNNC) Revenue Proportion by Product in 2024
Table 75. China National Nuclear Corporation (CNNC) Revenue Proportion by Application in 2024
Table 76. China National Nuclear Corporation (CNNC) Revenue Proportion by Geographic Area in 2024
Table 77. China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
Table 78. China National Nuclear Corporation (CNNC) Recent Developments
Table 79. IRE ELIT Corporation Information
Table 80. IRE ELIT Description and Major Businesses
Table 81. IRE ELIT Product Features and Attributes
Table 82. IRE ELIT Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. IRE ELIT Recent Developments
Table 84. Nordion Corporation Information
Table 85. Nordion Description and Major Businesses
Table 86. Nordion Product Features and Attributes
Table 87. Nordion Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Nordion Recent Developments
Table 89. Polatom Corporation Information
Table 90. Polatom Description and Major Businesses
Table 91. Polatom Product Features and Attributes
Table 92. Polatom Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Polatom Recent Developments
Table 94. Raw Materials Key Suppliers
Table 95. Distributors List
Table 96. Market Trends and Market Evolution
Table 97. Market Drivers and Opportunities
Table 98. Market Challenges, Risks, and Restraints
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Picture
Figure 2. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Carbon-14 Product Picture
Figure 4. Technetium-99m Product Picture
Figure 5. Iodine-131 Product Picture
Figure 6. Iodine-125 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Nuclear Medicine Diagnosis
Figure 10. Nuclear Medicine Treatment
Figure 11. Others
Figure 12. Radioisotopes for Nuclear Medicine Diagnosis and Treatment Report Years Considered
Figure 13. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 15. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Market Share by Region (2020-2031)
Figure 17. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Carbon-14 Revenue Market Share by Player in 2024
Figure 20. Technetium-99m Revenue Market Share by Player in 2024
Figure 21. Iodine-131 Revenue Market Share by Player in 2024
Figure 22. Iodine-125 Revenue Market Share by Player in 2024
Figure 23. Others Revenue Market Share by Player in 2024
Figure 24. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Market Share by Type (2020-2031)
Figure 25. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Market Share by Application (2020-2031)
Figure 26. North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 27. North America Top 5 Players Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) in 2024
Figure 28. North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Type (2020 - 2031)
Figure 29. North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 30. US Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 31. Canada Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 32. Mexico Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 33. Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 34. Europe Top 5 Players Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) in 2024
Figure 35. Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 36. Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 37. Germany Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 38. France Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 39. U.K. Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 40. Italy Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 41. Russia Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Top 8 Players Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) in 2024
Figure 44. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 45. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 46. Indonesia Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 47. Japan Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 48. South Korea Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 49. Australia Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 50. India Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 51. Indonesia Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 52. Vietnam Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 53. Malaysia Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 54. Philippines Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 55. Singapore Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 56. Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Central and South America Top 5 Players Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) in 2024
Figure 58. Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 59. Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 60. Brazil Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 61. Argentina Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 62. Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Middle East and Africa Top 5 Players Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) in 2024
Figure 64. South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 65. Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 66. GCC Countries Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 67. Israel Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 68. Egypt Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 69. South Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 70. Radioisotopes for Nuclear Medicine Diagnosis and Treatment Industry Chain Mapping
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
Table 1. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioisotopes for Nuclear Medicine Diagnosis and Treatment as of 2024)
Table 11. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Companies Headquarters
Table 13. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue by Application (2026-2031) & (US$ Million)
Table 21. Radioisotopes for Nuclear Medicine Diagnosis and Treatment High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Growth Accelerators and Market Barriers
Table 25. North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Growth Accelerators and Market Barriers
Table 27. Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Investment Opportunities and Key Challenges
Table 31. Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. NRG Corporation Information
Table 35. NRG Description and Major Businesses
Table 36. NRG Product Features and Attributes
Table 37. NRG Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. NRG Revenue Proportion by Product in 2024
Table 39. NRG Revenue Proportion by Application in 2024
Table 40. NRG Revenue Proportion by Geographic Area in 2024
Table 41. NRG Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
Table 42. NRG Recent Developments
Table 43. NTP Radioisotopes Corporation Information
Table 44. NTP Radioisotopes Description and Major Businesses
Table 45. NTP Radioisotopes Product Features and Attributes
Table 46. NTP Radioisotopes Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. NTP Radioisotopes Revenue Proportion by Product in 2024
Table 48. NTP Radioisotopes Revenue Proportion by Application in 2024
Table 49. NTP Radioisotopes Revenue Proportion by Geographic Area in 2024
Table 50. NTP Radioisotopes Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
Table 51. NTP Radioisotopes Recent Developments
Table 52. JSC Isotope Corporation Information
Table 53. JSC Isotope Description and Major Businesses
Table 54. JSC Isotope Product Features and Attributes
Table 55. JSC Isotope Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. JSC Isotope Revenue Proportion by Product in 2024
Table 57. JSC Isotope Revenue Proportion by Application in 2024
Table 58. JSC Isotope Revenue Proportion by Geographic Area in 2024
Table 59. JSC Isotope Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
Table 60. JSC Isotope Recent Developments
Table 61. ANSTO Corporation Information
Table 62. ANSTO Description and Major Businesses
Table 63. ANSTO Product Features and Attributes
Table 64. ANSTO Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. ANSTO Revenue Proportion by Product in 2024
Table 66. ANSTO Revenue Proportion by Application in 2024
Table 67. ANSTO Revenue Proportion by Geographic Area in 2024
Table 68. ANSTO Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
Table 69. ANSTO Recent Developments
Table 70. China National Nuclear Corporation (CNNC) Corporation Information
Table 71. China National Nuclear Corporation (CNNC) Description and Major Businesses
Table 72. China National Nuclear Corporation (CNNC) Product Features and Attributes
Table 73. China National Nuclear Corporation (CNNC) Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. China National Nuclear Corporation (CNNC) Revenue Proportion by Product in 2024
Table 75. China National Nuclear Corporation (CNNC) Revenue Proportion by Application in 2024
Table 76. China National Nuclear Corporation (CNNC) Revenue Proportion by Geographic Area in 2024
Table 77. China National Nuclear Corporation (CNNC) Radioisotopes for Nuclear Medicine Diagnosis and Treatment SWOT Analysis
Table 78. China National Nuclear Corporation (CNNC) Recent Developments
Table 79. IRE ELIT Corporation Information
Table 80. IRE ELIT Description and Major Businesses
Table 81. IRE ELIT Product Features and Attributes
Table 82. IRE ELIT Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. IRE ELIT Recent Developments
Table 84. Nordion Corporation Information
Table 85. Nordion Description and Major Businesses
Table 86. Nordion Product Features and Attributes
Table 87. Nordion Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Nordion Recent Developments
Table 89. Polatom Corporation Information
Table 90. Polatom Description and Major Businesses
Table 91. Polatom Product Features and Attributes
Table 92. Polatom Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Polatom Recent Developments
Table 94. Raw Materials Key Suppliers
Table 95. Distributors List
Table 96. Market Trends and Market Evolution
Table 97. Market Drivers and Opportunities
Table 98. Market Challenges, Risks, and Restraints
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Radioisotopes for Nuclear Medicine Diagnosis and Treatment Product Picture
Figure 2. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Carbon-14 Product Picture
Figure 4. Technetium-99m Product Picture
Figure 5. Iodine-131 Product Picture
Figure 6. Iodine-125 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Nuclear Medicine Diagnosis
Figure 10. Nuclear Medicine Treatment
Figure 11. Others
Figure 12. Radioisotopes for Nuclear Medicine Diagnosis and Treatment Report Years Considered
Figure 13. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 15. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Market Share by Region (2020-2031)
Figure 17. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Carbon-14 Revenue Market Share by Player in 2024
Figure 20. Technetium-99m Revenue Market Share by Player in 2024
Figure 21. Iodine-131 Revenue Market Share by Player in 2024
Figure 22. Iodine-125 Revenue Market Share by Player in 2024
Figure 23. Others Revenue Market Share by Player in 2024
Figure 24. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Market Share by Type (2020-2031)
Figure 25. Global Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue Market Share by Application (2020-2031)
Figure 26. North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 27. North America Top 5 Players Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) in 2024
Figure 28. North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Type (2020 - 2031)
Figure 29. North America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 30. US Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 31. Canada Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 32. Mexico Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 33. Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 34. Europe Top 5 Players Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) in 2024
Figure 35. Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 36. Europe Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 37. Germany Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 38. France Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 39. U.K. Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 40. Italy Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 41. Russia Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 42. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Top 8 Players Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) in 2024
Figure 44. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 45. Asia-Pacific Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 46. Indonesia Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 47. Japan Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 48. South Korea Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 49. Australia Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 50. India Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 51. Indonesia Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 52. Vietnam Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 53. Malaysia Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 54. Philippines Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 55. Singapore Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2031) & (US$ Million)
Figure 56. Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Central and South America Top 5 Players Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) in 2024
Figure 58. Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 59. Central and South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 60. Brazil Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 61. Argentina Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 62. Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue YoY (2020-2031) & (US$ Million)
Figure 63. Middle East and Africa Top 5 Players Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) in 2024
Figure 64. South America Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Type (2020-2031)
Figure 65. Middle East and Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (US$ Million) by Application (2020-2031)
Figure 66. GCC Countries Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 67. Israel Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 68. Egypt Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 69. South Africa Radioisotopes for Nuclear Medicine Diagnosis and Treatment Revenue (2020-2025) & (US$ Million)
Figure 70. Radioisotopes for Nuclear Medicine Diagnosis and Treatment Industry Chain Mapping
Figure 71. Channels of Distribution (Direct Vs Distribution)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232